{"entity":{"id":"nct05332561","kind":"trial","name":"Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)","aka":[],"tldr":"This study tests a PARP inhibitor; the registry reports that it is recruiting.","summary":"The registry lists NCT05332561 as recruiting, last updated 2025-03-20. Enrolment is 240 planned participants, an estimate. Interventions: Atezolizumab 1200 mg in 20 ML Injection, Inavolisib, Ipatasertib, Olaparib, Sacituzumab govitecan, Trastuzumab/pertuzumab. Primary measures include Invasive Disease-free Survival (IDFS) as defined by Hudis et al in the entire study population four years after surgery. No results are posted in the registry; this does not exclude separate publications.","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT05332561","url":"https://clinicaltrials.gov/study/NCT05332561"}],"tags":[],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":["parp"],"drugs":["olaparib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05332561","phase":"2","setting":"Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer - a Multicenter, Open-label, Umbrella Phase-II Study - COGNITION-GUIDE","sponsor":"German Cancer Research Center","started":"2023-06-29","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05332561/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}]}}